#United States #New York #Class Action #Pacira BioSciences #PCRX

Gross Law Firm Alerts Pacira BioSciences Shareholders

The Gross Law Firm has issued a significant notification for shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX), highlighting an impending class action lawsuit that could have profound implications for those who invested in the company during the specified class period. Shareholders who acquired shares of PCRX from August 2, 2023, to August 8, 2024, are particularly encouraged to step forward.

Background of the Case

The alert follows a troubling announcement made on August 9, 2024, by Pacira, in which it disclosed the outcome of a lawsuit aimed at eVenus regarding a patent infringement claim. According to this press release, a court ruling deemed the U.S. Patent No. 11,033,495, pivotal for the company’s primary revenue-generating product Exparel, as invalid. This patent accounts for approximately 80% of Pacira's revenue, raising alarms about the potential influx of generic competitors in the market and escalating litigation costs moving forward.

The impact of this announcement was immediate and severe; Pacira’s stock price plummeted over 47% in one day, dropping from a closing price of $22.36 per share on August 8, 2024, to a low of $11.70 on August 9, 2024.

Call to Action for Shareholders

Given these developments, the Gross Law Firm is urging affected shareholders to contact the firm to explore the possibility of being appointed as lead plaintiff in this class action. However, it's essential to note that being named as a lead plaintiff is not a prerequisite to partake in any potential recovery from this lawsuit.

The deadline for shareholders to register for this class action lawsuit is March 14, 2025. To register and ensure that you keep abreast of developments in this case, shareholders are encouraged to use the following link: Register Here.

What’s Next for Shareholders?

Once you register as a participant in this class action, you'll gain access to portfolio monitoring services which will provide regular updates on the status of the case. This initiative aims to keep investors informed and engaged throughout the lifecycle of the legal proceedings, ensuring that their rights are protected.

Why Choose Gross Law Firm?

The Gross Law Firm is a nationally recognized entity specializing in class action lawsuits and is dedicated to safeguarding the rights of investors who have suffered losses due to fraudulent activities or business malpractice. The firm prioritizes responsible business practices and advocates for transparency in corporate governance.

In the face of this unfortunate scenario for Pacira BioSciences investors, ensuring participation in the class action could be crucial. The Gross Law Firm remains committed to routing recovery efforts for those impacted by this troubling announcement and subsequent stock price drop.

For further inquiries, you can reach out to:
- The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

Stay informed and take action before the registration deadline to protect your interests as a shareholder of Pacira BioSciences, Inc.